Tumor molecular profiling could reduce endometrial cancer therapy by 20%
Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study
11 May 2021Study: Long-term benefits of mindfulness intervention to reduce stress, burnout
11 May 2021Tumor molecular profiling could reduce endometrial cancer therapy by 20%
A retrospective study conducted by scientists from the Comprehensive Cancer Center (CCC) of MedUni Vienna and Vienna General Hospital found that compiling a tumor molecular profile can result in better risk stratification and hence to better treatment decisions in endometrial cancer. The use of so-called “integrated molecular risk classification” could reduce the use of chemo- and radiotherapies aimed at preventing metastases following hysterectomy by up to 20%. The researchers were also able to demonstrate the feasibility of compiling this tumor molecular profile as part of the clinical routine.
